Does Eloralintide Protect Muscle Better Than a GLP-1?

Eloralintide is the compound every peptide vendor started talking about the moment Lilly published its Phase 2 results. The pitch is consistent wherever you read it: same weight loss as a GLP-1, far less nausea, and it spares muscle. For anyone dieting who has spent years building the muscle they are now trying not to lose, that last claim is the one that sells.

So I went looking for the study behind it.

Eloralintide is not a GLP-1, and the difference is real

Half the confusion around this compound comes from people filing it next to semaglutide. It does not belong there.

Eloralintide (development code LY3841136) is a selective amylin receptor agonist. Amylin is the hormone your beta cells co-secrete with insulin at every meal, and its job is to tell your hindbrain the meal is over. It has nothing to do with the GLP-1 receptor.

The receptor itself is an odd piece of biology. There is no amylin gene sitting in your genome waiting to be activated. Amylin receptors are built: the calcitonin receptor pairs up with one of three receptor activity-modifying proteins, RAMP1, RAMP2 or RAMP3, and the resulting complexes are what we call AMY1, AMY2 and AMY3 (Christopoulos et al., 1999). Different partner protein, different binding profile.

That matters because it turns "selective" into something measurable rather than marketing. In Lilly's own pharmacology work, eloralintide preferentially activated human AMY1R by 12-fold over the plain calcitonin receptor and 11-fold over AMY3R (Briere et al., 2025). Cagrilintide, the Novo Nordisk molecule inside CagriSema, hits both amylin and calcitonin receptors. That extra calcitonin activity is the leading explanation for why cagrilintide makes people feel worse.

The practical consequence sits in your labs. Amylin suppresses glucagon and slows gastric emptying, so fasting glucose and HbA1c tend to drift down. But amylin's glucagon suppression is glucose-sensitive: it eases off when blood sugar falls, which leaves your counter-regulatory response intact. GLP-1 agonism does not have that built-in brake in the same way. Head-to-head infusion work in humans also found GLP-1 slows gastric emptying harder than amylin does (Asmar et al., 2010), which is the mechanical reason the GI misery differs between the classes.

Where the muscle-sparing claim actually comes from

Here is the part nobody selling this compound will show you.

The claim has two parents, and both of them are rodents.

The first is a 2006 paper in which diet-induced obese rats given amylin lost three times more fat than pair-fed controls eating the same amount of food. The pair-fed rats lost significant lean tissue. The amylin rats did not (Roth et al., 2006). That is a genuinely interesting result and it is the mechanistic seed of the whole idea. It is also twenty years old, in rats, using native amylin rather than eloralintide.

The second is one line in Lilly's own discovery paper: eloralintide "dose dependently reduced food intake and lowered body weight, primarily through fat mass loss, in diet-induced obese rats" (Briere et al., 2025). The same paper reports that eloralintide caused significantly less conditioned taste avoidance in lean rats than cagrilintide, which is the animal proxy for nausea.

That is the entire evidentiary base. Rats.

A claim that has not been measured cannot be wrong yet. It also cannot be relied on.

What the human data does show

Two eloralintide trials have been published, and both are worth knowing properly.

Phase 1 enrolled 100 participants with obesity or overweight across five ascending-dose cohorts for 12 weeks, with no dose escalation. Weight loss ran from 2.6 percent to 11.3 percent depending on dose. The GI events were strikingly mild: diarrhoea 10 percent, nausea 8 percent, vomiting 4 percent (Bhattachar et al., 2026).

Phase 2 is the one that made the headlines. 263 participants across 46 US centres, randomised to placebo or one of six eloralintide arms, for 48 weeks (Billings et al., 2025):

Read that nausea column again, because it changes the story the vendors tell.

The low-nausea reputation is about titration, not amylin

The 6mg fixed-dose arm produced 64 percent nausea. That is not a gentle drug. The 9mg arm, a higher dose, produced half that, because it was reached differently. And the 3 to 9mg escalating arm delivered 16 percent weight loss on 25 percent nausea, barely above the 14 percent placebo rate.

So "amylin agonists do not cause nausea" is wrong. What the data actually supports is narrower and more useful: start low and climb slowly and this class is tolerable, jump straight to a mid dose and it is not. That is the same lesson tirzepatide and retatrutide teach. The mechanism is milder. It is not free.

The trade-off nobody mentions when selling you the class

If you want to know what an amylin analog does to human body composition, eloralintide cannot tell you. Nothing can, yet. But the wider picture across obesity drugs is now well characterised, and it does not support the framing.

The largest analysis available pooled 262 trials covering 99,791 participants across 19 drugs (Nong et al., 2026). Its body composition finding is one sentence and worth sitting with:

Tirzepatide reduced fat mass the most, by 25.7 percent, but also lean mass the most, by 8.3 percent.

That is the actual relationship. The drug that strips the most fat strips the most lean, because losing weight faster means losing more of everything. Lean mass loss is not a quirk of GLP-1 receptor agonism that a different receptor would avoid. It is the cost of the deficit.

For a compound to genuinely break that pattern, it would have to produce a given amount of fat loss with less lean loss than any other route to the same deficit. Nobody has shown eloralintide doing that, because nobody has measured it. That analysis found no body composition data for any amylin agonist at all.

There is one human dataset that gets close, and it is not encouraging. A DXA substudy of 252 REDEFINE-1 participants, presented at ObesityWeek 2025 and still not published in a journal, split the weight loss into fat and lean for each arm. CagriSema came out at 66.9 percent fat and 33.1 percent lean. Semaglutide alone managed 69.7 and 30.3. Cagrilintide alone, the pure amylin analog, was the worst of the three at 62.9 and 37.1.

Treat those numbers with the caution conference data deserves, and note it is a different molecule from eloralintide. But it is the closest look anyone has had at what an amylin analog does to human body composition, and the amylin arm lost proportionally more lean tissue than the GLP-1 arm did.

GLP-1s may not be the muscle-wasting villain either

The premise underneath the whole amylin pitch is that GLP-1 drugs strip lean mass. The best data available complicates that too.

The SURMOUNT-1 DXA substudy followed 160 people on tirzepatide for 72 weeks: 21.3 percent total weight loss, 33.9 percent fat mass loss, 10.9 percent lean mass loss (Look et al., 2025). Roughly 75 percent of the weight lost was fat. That ratio was not meaningfully different from the placebo group's, which also ran about 75:25. That's the detail that matters.

In other words, tirzepatide was not preferentially eating muscle. It was producing the fat-to-lean split that losing weight produces. The problem eloralintide claims to solve may be considerably smaller than the pitch requires.

I went through the same question for retatrutide and the TRIUMPH-1 data in how much muscle you actually lose on retatrutide, and the answer there was similar: the drug is not the variable that decides it.

Eloralintide against tirzepatide and retatrutide

This is the comparison everyone wants, so here it is with the caveat that has to come first.

Sources for the table, in order: eloralintide Phase 2 (Billings et al., 2025), SURMOUNT-1 (Jastreboff et al., 2022), the retatrutide Phase 2 trial (Jastreboff et al., 2023), REDEFINE 1 (Garvey et al., 2025) and STEP 1 (Wilding et al., 2021).

Eloralintide lands in the same territory as tirzepatide, below retatrutide at the top end, and does it as a single-receptor drug. That is a real achievement.

What it does not have is a combination result. Lilly is running eloralintide with tirzepatide in NCT06603571, and a Phase 1 PK study (NCT06916065) has completed, but no human combination data has been published. If you see a weight loss percentage attached to the pairing, check where it came from. At least one outlet ran a "combo" headline over a story whose own body text described the monotherapy Phase 1 results, and that error has propagated.

If you want the closest honest proxy for what an amylin adds on top of a GLP-1, use REDEFINE-1: cagrilintide alone managed 11.8 percent, semaglutide alone 16.1 percent, and together 20.4 to 22.7 percent depending on estimand. The amylin component added something. It did not double anything.

Should you run baseline labs if you are already on TRT or a cycle?

Yes, and the reasoning is not generic caution.

Work through it:

Are you using exogenous insulin or a sulfonylurea? If yes, this is the single highest-risk interaction in this article and the section below is the most important thing on the page. Baseline labs plus daily glucose self-monitoring, not a panel every three months.

Are you on TRT or a cycle without insulin? Testosterone does not interact with amylin signalling in any established way. Your reason for baseline labs is different: rapid weight loss changes ALT, HDL, triglycerides and haematocrit on its own, and without a baseline you will spend the next six months unable to tell which change came from which compound.

Are you already running a GLP-1 or dual agonist? Then you are stacking two drugs that both slow gastric emptying, and the GI ceiling arrives sooner than either alone suggests.

Is your food intake about to drop sharply? Then potassium, sodium and magnesium belong on the panel, because appetite suppressants work by making you eat less and electrolytes follow food.

The insulin interaction, with real numbers

Eloralintide has no long-term human safety record. But amylin analogs are not new. Pramlintide has been approved since 2005, and it carries an FDA boxed warning for severe hypoglycaemia when combined with insulin.

The pooled trial data behind that warning: in type 1 diabetes over the first three months, severe hypoglycaemia occurred in 16.8 percent of patients on pramlintide plus insulin versus 10.8 percent on insulin alone. In type 2 diabetes the absolute numbers are lower but the relative jump is larger, 8.2 percent versus 2.1 percent. Events cluster within two to three hours of injection. The mandated mitigation is specific: cut mealtime insulin by 50 percent at initiation, then re-titrate.

A meta-analysis of ten pramlintide trials confirmed the pattern of improved HbA1c alongside increased hypoglycaemia (Qiao et al., 2017).

The mechanism transfers even where the magnitude has not been measured. Amylin suppresses glucagon, glucagon is your primary defence against falling blood sugar, and removing part of that defence while injecting insulin is how people end up unconscious. Eloralintide's trials excluded insulin users, so nobody has measured this for this molecule. Treat the pramlintide rule as the floor, not the ceiling, and do not train fasted while you work it out.

Pancreatitis is a GLP-1 signal, not an amylin one

You will see pancreatitis warnings copied onto amylin content. They do not belong there, and the distinction is worth getting right.

The GLP-1 class does carry a measurable signal. A 2025 meta-analysis of 62 randomised trials covering 66,232 patients found a relative risk of 1.44 for pancreatitis on GLP-1 receptor agonists (Wen et al., 2025). That is real and modest.

Pramlintide's label lists pancreatitis only as a post-marketing spontaneous report, with no incidence rate and no trial signal. Eloralintide's trials reported serious adverse events at 5.3 percent versus 5.4 percent on placebo.

So lipase and amylase are not a routine amylin monitoring requirement the way they are on a GLP-1. Check them if you have symptoms, meaning epigastric pain radiating to the back with vomiting. Do not check them monthly because a blog told you to.

What to actually monitor

Draw at trough, just before your weekly dose, and keep every follow-up draw at the same point relative to injection day. Otherwise you are measuring your dosing schedule rather than your physiology.

Baseline, before the first dose: fasting glucose, HbA1c, fasting insulin, HOMA-IR, a full electrolyte panel, creatinine and eGFR, ALT and AST, and a lipid panel.

At 4 weeks: glucose and electrolytes, if your intake has genuinely dropped.

At 8 to 12 weeks: repeat the full panel.

Daily, if you use insulin: glucose self-monitoring around the injection window.

If you are running a GLP-1 or dual agonist alongside this, the panel is broader and the reasoning differs in places. That is covered in the GLP-1 bloodwork guide and, for the triple agonist specifically, the retatrutide monitoring guide.

Working out your own HOMA-IR

HOMA-IR is the number that tells you whether fat loss is buying you metabolic improvement or just a smaller body. The formula:

HOMA-IR = (fasting glucose in mmol/L × fasting insulin in mIU/L) / 22.5

Say you start at glucose 5.4 mmol/L and insulin 14 mIU/L. That is (5.4 × 14) / 22.5 = 3.36, which is meaningful insulin resistance. Twelve weeks later at glucose 5.0 and insulin 7: (5.0 × 7) / 22.5 = 1.56. Under 2.0 is generally considered healthy insulin sensitivity.

Note what moved. Glucose barely shifted. Insulin halved. If you had tracked glucose alone you would have concluded nothing was happening.

The supply problem nobody wants to say out loud

"Where can I buy eloralintide" is one of the most common searches attached to this compound, so let me answer it directly.

You cannot, legitimately. It is an investigational Lilly molecule in active Phase 2 development. It has not been approved by the FDA, the EMA, the TGA, or anyone else. There is no legal supply chain and no legitimate pharmacy source.

That is a different situation from a well-characterised research peptide. With BPC-157 you can at least buy a reference standard and test against it. With eloralintide there is no reference material outside Lilly, no published analytical method, and no realistic way for a third-party lab to confirm that what is in the vial is what the label claims. The honest risk assessment is not "it might be underdosed." It is that you have no way of knowing what you are injecting.

If that seems overly cautious, remember that this class produces 64 percent nausea at the wrong dose, and you would be guessing at the dose.

What actually preserves muscle while you diet

Since the drug cannot yet claim it, here is what can.

Protein. In a randomised trial putting men in a 40 percent energy deficit with six training sessions a week, the group eating 2.4 g/kg/day gained 1.2 kg of lean mass while losing 4.8 kg of fat. The 1.2 g/kg group gained essentially nothing and lost less fat (Longland et al., 2016). That is a larger, better-evidenced body composition effect than anything published for any drug in this article.

Rate of loss. Elite athletes losing weight slowly retained more lean mass and strength than those losing it fast (Garthe et al., 2011). The practical range for resistance-trained athletes is 0.5 to 1.0 percent of bodyweight per week, and fat-free mass is better preserved at the lower end (Ruiz-Castellano et al., 2021).

This is the awkward part for anyone excited about the compound. A 20 percent weight loss over 48 weeks is roughly 0.4 percent per week, which is fine. But most people running these drugs lose far faster early on, and the drug's appetite suppression makes hitting 2.4 g/kg of protein genuinely difficult. The compound can quietly work against the two things that actually protect your muscle.

Rate of loss also drives the other thing people regret after a big cut, which is what happens to your skin.

Key takeaways

• Eloralintide is a selective amylin receptor agonist, not a GLP-1. It works through a different receptor complex and a milder, glucose-sensitive mechanism.
• No human body composition data exists for it. The muscle-sparing claim comes from diet-induced obese rats and nothing else.
• Across 262 trials, the drug that lost the most fat (tirzepatide, 25.7 percent) also lost the most lean mass (8.3 percent). Lean loss tracks the size of the deficit, not the receptor.
• The one human amylin body composition dataset, cagrilintide alone in REDEFINE-1, had a worse fat-to-lean split than semaglutide alone. It is conference data, not peer-reviewed, but it points away from the marketing.
• Tirzepatide's 75:25 fat-to-lean split was indistinguishable from placebo, so the problem being solved may be smaller than advertised.
• Phase 2 weight loss of 9 to 20 percent over 48 weeks is genuine and competitive.
• Low nausea depends on titration. The 6mg fixed-dose arm hit 64 percent nausea; the escalating 3 to 9mg arm hit 25 percent.
• If you use exogenous insulin, the pramlintide precedent is a 50 percent mealtime insulin reduction at initiation. This is the one genuinely dangerous interaction.
• Pancreatitis is a GLP-1 class signal, not an amylin one. Do not monitor lipase routinely on that basis.
• Protein at 2.4 g/kg and a loss rate under 1 percent per week remain better evidenced for lean mass than any drug here.

---

References

1. Billings, L. K., Hsia, S., Bays, H., Tidemann-Miller, B., O'Hagan, J., Tham, L. S., Butler, A., Kazda, C., Mather, K. J., & Coskun, T. (2025). Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. The Lancet, 406(10520), 2631-2643. PubMed
2. Bhattachar, S., Tham, L. S., Tidemann-Miller, B., Ibriga, H., Qu, H., Briere, D. A., Haupt, A., Mather, K. J., & Pratt, E. (2026). Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept. Diabetes, Obesity and Metabolism, 28(4), 2651-2660. PubMed
3. Briere, D. A., Qu, H., Lansu, K., He, M. M., Moyers, J. S., Coskun, T., Long, A., Allen, D., O'Farrell, L., Bowen, B., Pratt, E., Tidemann-Miller, B., Tham, L. S., Ibriga, H., Alsina-Fernandez, J., Mather, K. J., Haupt, A., & Bhattachar, S. N. (2025). Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept. Molecular Metabolism, 102, 102271. PubMed
4. Roth, J. D., Hughes, H., Kendall, E., Baron, A. D., & Anderson, C. M. (2006). Antiobesity effects of the beta-cell hormone amylin in diet-induced obese rats: effects on food intake, body weight, composition, energy expenditure, and gene expression. Endocrinology, 147(12), 5855-5864. PubMed
5. Look, M., et al. (2025). Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes, Obesity and Metabolism, 27(5), 2720-2729. PubMed
6. Garvey, W. T., et al. (2025). Coadministered cagrilintide and semaglutide in adults with overweight or obesity. The New England Journal of Medicine, 393(7), 635-647. PubMed
7. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. The New England Journal of Medicine, 387(3), 205-216. PubMed
8. Jastreboff, A. M., Kaplan, L. M., Frias, J. P., et al. (2023). Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. The New England Journal of Medicine, 389(6), 514-526. PubMed
9. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. The New England Journal of Medicine, 384(11), 989-1002. PubMed
10. Christopoulos, G., Perry, K. J., Morfis, M., Tilakaratne, N., Gao, Y., Fraser, N. J., Main, M. J., Foord, S. M., & Sexton, P. M. (1999). Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product. Molecular Pharmacology, 56(1), 235-242. PubMed
11. Asmar, M., Bache, M., Knop, F. K., Madsbad, S., & Holst, J. J. (2010). Do the actions of glucagon-like peptide-1 on gastric emptying, appetite, and food intake involve release of amylin in humans? The Journal of Clinical Endocrinology and Metabolism, 95(5), 2367-2375. PubMed
12. Qiao, Y. C., Ling, W., Pan, Y. H., et al. (2017). Efficacy and safety of pramlintide injection adjunct to insulin therapy in patients with type 1 diabetes mellitus: a systematic review and meta-analysis. Oncotarget, 8(39), 66504-66515. PubMed
13. Wen, J., et al. (2025). Evaluating the rates of pancreatitis and pancreatic cancer among GLP-1 receptor agonists: a systematic review and meta-analysis of randomised controlled trials. Endocrinology, Diabetes and Metabolism, 8(5), e70113. PubMed
14. Longland, T. M., Oikawa, S. Y., Mitchell, C. J., Devries, M. C., & Phillips, S. M. (2016). Higher compared with lower dietary protein during an energy deficit combined with intense exercise promotes greater lean mass gain and fat mass loss: a randomized trial. The American Journal of Clinical Nutrition, 103(3), 738-746. PubMed
15. Garthe, I., Raastad, T., Refsnes, P. E., Koivisto, A., & Sundgot-Borgen, J. (2011). Effect of two different weight-loss rates on body composition and strength and power-related performance in elite athletes. International Journal of Sport Nutrition and Exercise Metabolism, 21(2), 97-104. PubMed
16. Ruiz-Castellano, C., Espinar, S., Contreras, C., Mata, F., Aragon, A. A., & Martinez-Sanz, J. M. (2021). Achieving an optimal fat loss phase in resistance-trained athletes: a narrative review. Nutrients, 13(9), 3255. PubMed
17. Nong, K., Shi, Q., Xie, X., Wang, Y., Agarwal, A., Guyatt, G. H., et al. (2026). Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis. BMJ, 394, e372161. PubMed